Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors.

ABSTRACT: Immune checkpoint inhibitors (ICIs) have been approved for monotherapy and combined therapy with chemotherapy and/or radiotherapy in China since 2018. The number of patients receiving ICIs has significantly increased in recent years, and the collection and analysis of this data are crucial for a comprehensive understanding of their clinical outcomes and adverse effects. The effects of ICIs may vary among different ethnic groups, and there is a lack of such data in the Chinese population. This study aimed to investigate the occurrence rate of various types of immune-related adverse events (irAEs) of ICIs in cancer survivors with different types of cancer and explore the associated risk factors. Demographic data, cancer type, dosage, Eastern Cooperative Oncology Group Performance Score (ECOG

SUBMITTER: Zhang Q 

PROVIDER: S-EPMC11681080 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature